Effect of RvD<sub>2</sub> on LTD<sub>4</sub>–pretreated human bronchi in response to pharmacologically-induced tone and 5-LOX/CysLTR1 expression. Rayan Khaddaj-Mallat Chantal Sirois Marco Sirois Edmond Rizcallah Sofia Marouan Caroline Morin Éric Rousseau 10.1371/journal.pone.0167058.g001 https://plos.figshare.com/articles/figure/Effect_of_RvD_sub_2_sub_on_LTD_sub_4_sub_pretreated_human_bronchi_in_response_to_pharmacologically-induced_tone_and_5-LOX_CysLTR1_expression_/4307288 <p><b>a.</b> Corresponding bar graph showing mean contractile amplitudes induced by 1 μM methacholine (MCh), 1 μM histamine or 30 nM U-46619, either under control (untreated) conditions or after 1 μM LTD<sub>4</sub> pre-treatment in the absence or presence of 300 nM RvD<sub>2</sub> (n = 7–22, *<i>P</i> < 0.05). <b>b.</b> Western blot analyses of the 5-LOX / β-actin ratio assessing the putative effects of 1 μM LTD<sub>4</sub> and 1 μM LTD<sub>4</sub> + 300 nM RvD<sub>2</sub> on human bronchial homogenates compared with control conditions (<i>n</i> = 6, *<i>P</i> < 0.05). <b>c.</b> Western blot analyses using <a href="http://www.ejog.org/action/doSearch?searchType=quick&occurrences=all&ltrlSrch=true&searchScope=series&searchText=CysLTR1&seriesISSN=0301-2115" target="_blank">CysLTR1</a> and β-actin antibodies. Densities of the immunoreactive bands are expressed as a function of the β-actin-immunoreactive band (<i>n</i> = 6, * <i>P</i> < 0.05).</p> 2016-12-09 21:19:16 cysteinyl leukotriene receptor 1 WRW 300 nM RvD 2 Resolvin D 2 ALX RvD 2 RvD 2 treatments ASM p 38-MAP kinase 1 μ M LTD 4 LOX LTD 4 TNF bronchi